Karo Bio recieves European patent

KARO BIO RECIEVES EUROPEAN PATENT

* THE DEVELOPMENT OF A NEW GENERATION OF PHARMACEUTICALS TARGETING THE
ESTROGEN RECEPTOR BETA SECURED BY PATENT

* UNIQUE OPPORTUNITIES IN WOMEN’S HEALTH CARE

Karo Bio AB was today granted patent by the European Patent Office on the
estrogen receptor beta. The Patent, which covers 17 European countries, gives
Karo Bio and its partner, Merk & Co. exclusive rights in Europe in the
isolated receptor and its use in drug discovery and design methods.

The grant of a patent gives Karo Bio and its Pharmaceutical collaborator Merck
Inc. unique opportunities to develop safe and more potent pharmaceuticals for
treatment of a variety of important diseases.

“The granted estrogen receptor beta patent significantly adds to Karo Bio’s
extensive proprietary technology in the estrogen field, including also
structural information of the estrogen receptor alpha and beta targets”, says
Per Otteskog, Executive Vice President Research & Development of Karo Bio.

Estrogen therapy in use today can protect women from development of
postmenopausal symptoms, osteoporosis and cardiovascular diseases. Conversely,
antagonists of estrogen are useful for treatment of breast cancer. However,
the pharmaceuticals in use today do not discriminate between the two receptor
forms and may also have significant draw backs regarding side effects.

The estrogen receptor beta@has a unique distribution and function in different
tissues and organs in comparison to the estrogen receptor alpha. This provides
the opportunity for development of a completely new class of receptor subtype
selective pharmaceuticals for treatment of a variety of disorders.

Nuclear receptors function as molecular locks for hormonal keys such as sex
hormones and thyroid hormones. The hormones activate the receptor to take part
in the regulation of certain genes, which play a central role in cell and
tissue functions. They are thus important pharmaceutical targets for
developing more effective pharmaceuticals.

Visit us on https://www.karobio.se/

For further information, please contact:

Per Otteskog, Executive Vice President Research & Development of Karo Bio,
Tel: +46/8/6086018

Karo Bio AB is a research based pharmaceutical company that develops drugs
that acts via nuclear receptors for the treatment of major diseases, such as
osteoporosis, type 2 diabetes, cancer, cardiovascular disease and metabolic
disorders. The company has a leading position within this field, and
development programs are carried out in collaboration with international
pharmaceutical companies. The company has about 80 employees, and is located
at the Novum research complex adjacent to Huddinge University hospital. In
addition, Karo Bio has a subsidiary in San Francisco and a comprehensive,
international scientific network. The company is listed on the Stockholm Stock
Exchange and has collaboration agreements with Bristol-Myers Squibb and Merck
& Co.

————————————————————
Please visit https://www.bit.se for further information
The following files are available for download:
https://www.bit.se/bitonline/1999/08/11/19990811BIT00150/bit0001.doc
https://www.bit.se/bitonline/1999/08/11/19990811BIT00150/bit0002.pdf